Physician

Lalita Hemant Pandit, M.D.

According to 2025 Medicare claims, Lalita Pandit, M.D. (NPI: 1578521266) practices hematology/oncology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is LALITA PANDIT MD INC (NPI: 1437269420; TIN: 331035337) and primary practice location at 92708-7505. Pandit is affiliated with the Family Choice ACO, LLC (ACO ID: A3770), participating under the MSSP model.

Pandit's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 523 traditional Medicare patients, billed 162,174 HCPCS/CPT codes, and received $2,980,314 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,886 prescription claims across 279 beneficiaries totaling $5,510,937 in drug costs, led by Xtandi (Enzalutamide). DME data shows 25 claims. Open Payments data shows 111 records totaling $3,659. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,772,378 to $2,980,314. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,214,188 to $5,510,937. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,303 and ending at $2,222.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	587	195,924	$1,772,378
2016	573	204,262	$2,521,794
2017	492	154,731	$2,063,319
2018	501	143,248	$1,949,225
2019	485	182,900	$1,811,900
2020	467	200,688	$2,079,966
2021	496	251,467	$2,881,997
2022	530	206,164	$2,530,085
2023	507	179,766	$2,574,199
2024	523	162,174	$2,980,314

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	168	1,642	$1,214,188
2016	165	1,706	$1,251,029
2017	163	1,533	$1,533,594
2018	161	1,333	$1,637,075
2019	168	1,347	$2,077,413
2020	192	1,572	$2,915,740
2021	247	1,706	$4,121,752
2022	293	1,699	$3,888,886
2023	266	1,507	$4,539,534
2024	279	1,886	$5,510,937

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	22	$199
2017	N/R	54	$8,004
2018	N/R	107	$4,680
2019	N/R	262	$11,809
2020	N/R	144	$4,962
2021	N/R	158	$5,598
2022	N/R	44	$3,139
2023	N/R	44	$5,037
2024	N/R	25	$569

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	98	163	$147
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	456	1,364	$102
36415	Insertion of needle into vein for collection of blood sample	405	1,844	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	394	1,517	$8
J7050	Infusion, normal saline solution, 250 cc	72	797	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	50	1,500	$685,326
Imbruvica	Ibrutinib	39	1,140	$654,210
Brukinsa	Zanubrutinib	38	1,140	$576,569
Lenalidomide	Lenalidomide	26	665	$302,322
Jakafi	Ruxolitinib Phosphate	16	480	$288,190

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$325
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	111	$3,659	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lalita Hemant Pandit, M.D.?

Tedicare shows public-source Medicare data for Lalita Hemant Pandit, M.D. (NPI 1578521266), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lalita Hemant Pandit, M.D. have ACO affiliation data?

Lalita Hemant Pandit, M.D. is shown with ACO affiliation data for Family Choice ACO, LLC (MSSP, ACO ID A3770).

What billing organization is linked to Lalita Hemant Pandit, M.D.?

Lalita Hemant Pandit, M.D. is linked to LALITA PANDIT MD INC (billing NPI 1437269420) in the available physician profile data.

Does Lalita Hemant Pandit, M.D. have Open Payments data?

Lalita Hemant Pandit, M.D. has 111 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.